Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet

Pharmacotherapy

Volumn 27, Issue 8, 2007, Pages 1120-1124

  Erdman, Keith ^a,c   Stypinski, Daria ^b   Combs, Michelle ^b   Witt, Patricia ^a   Stiles, Mark ^b   Pollock, Steve ^a  

^a Schwarz Pharma Inc   (United States)

^b MDS Inc   (Canada)

^c 206 Carnegie Center   (United States)

Author keywords

Alprazolam; Food effect; Orally disintegrating tablet; Pharmacokinetics

Indexed keywords

ALPRAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; TABLETS; TANDEM MASS SPECTROMETRY;

EID: 34547486616     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.8.1120     Document Type: Article

References (10)

1. Pharmacia and Upjohn Company. Xanax (aprazolam tablets) package insert. Kalamazoo, MI; 2001. Available from http://www.pfizer.com/pfizer/ download/uspi_xanax.pdf. Accessed October 19, 2006.
2. Schwarz Pharma, Inc. Niravam (aprazolam orally disintegrating tablets) package insert. Milwaukee, WI; 2005. Available from http://www.schwarzusa.com/Product_files/ PIs/NiravamFullPI.pdf. Accessed October 19, 2006.
3. Eller MG, Della-Coletta AA. Absence of effect of food on alprazolam absorption from sustained release tablets. Biopharm Drug Dispos 1990;11:31-7.
4. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-80.
5. U.S. Food and Drug Administration. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies, December 2002. Available from http://www.fda.gov/cder/ guidance/5194fnl.htm. Accessed October 19, 2006.
6. Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992;149:1556-62.
7. Ciraulo DA, Antal EJ, Smith RB, et al. The relationship of alprazolam dose to steady-state plasma concentrations. J Clin Psychopharmacol 1990;10:27-32.
8. Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:715-22.
9. Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry 1993;54(suppl):4-11; discussion 12-14.
10. Pecknold J, Luthe L, Munjack D, Alexander P. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 1994;14:314-21.